Note: This document contains side effect information about mitomycin. Some of the dosage forms listed on this page may not apply to the brand name Mutamycin.
Applies to mitomycin: intravenous powder for solution
Intravenous route (Powder for Solution)
Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin injection. Hemolytic Uremic Syndrome (HUS) has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during therapy with mitomycin, but most cases occur at doses greater than or equal to 60 mg. Blood product transfusion may exacerbate the symptoms associated with this syndrome.
Along with its needed effects, mitomycin (the active ingredient contained in Mutamycin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Also, because of the way cancer medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer. Discuss these possible effects with your doctor.
Check with your doctor immediately if any of the following side effects occur while taking mitomycin:
Check with your doctor as soon as possible if any of the following side effects occur while taking mitomycin:
Some side effects of mitomycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return.
After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:
Also, check with your doctor if you notice any of the following:
Applies to mitomycin: compounding powder, intravenous powder for injection
Very common (10% or more): Bone marrow toxicity (64%), thrombocytopenia, leucopenia, pancytopenia, neutropenia, granulocytopenia, erythropenia, microangiopathic hemolytic anemia, myelodysplastic syndrome, thrombotic thrombocytopenic purpura
Very common (10% or more): Fever (14%)
Frequency not reported: Fatigue, edema, pain
Common (1% to 10%): Allergic skin rash, contact dermatitis, palmar-plantar erythema, pruritus, exanthema, integument and mucous membrane toxicity
Uncommon (0.1% to 1%): Alopecia
Common (1% to 10%): Interstitial pneumonia, dyspnea, cough, shortness of breath
Rare (less than 0.1%): Pulmonary hypertension, pulmonary veno-occlusive disease (PVOD)
Common (1% to 10%): Renal dysfunction, increase in serum creatinine, glomerulopathy, nephrotoxicity
Rare (less than 0.1%): Hemolytic uremic syndrome (HUS) (commonly fatal), microangiopathic-hemolytic anemia (MAHA syndrome)
Rare (less than 0.1%): Heart failure (after previous therapy with anthracyclines)
Very common (10% or more): Anorexia (14%), nausea (14%), vomiting (14%)
Uncommon (0.1% to 1%): Mucositis, stomatitis, diarrhea
Common (1% to 10%): Cystitis (possibly hemorrhagic), dysuria, nocturia, pollakiuria, hematuria, local irritation of the bladder wall
Very rare (less than 0.01%): Necrotizing cystitis, allergic (eosinophilic) cystitis, stenosis of the efferent urinary tract, reduced bladder capacity, bladder wall calcification, bladder wall fibrosis, bladder perforation
Frequency not reported: Increased frequency of micturition, rash and pruritus on hands and genital area
Postmarketing reports: Bladder fibrosis/contraction rarely requiring cystectomy
Very rare (less than 0.01%): Severe allergic reaction
Rare (0.01% to 0.1%): Life-threatening infection (e.g., bacterial, viral, fungal), sepsis, hemolytic anemia
Frequency not reported: Septic shock
Common (1% to 10%): Following extravasation: Cellulitis, tissue necrosis
Frequency not reported: Blurred vision
Frequency not reported: Confusion
Rare (less than 0.1%): Liver dysfunction, increased transaminases, jaundice, veno-occlusive disease (VOD)
Frequency not reported: Myelodysplastic syndrome, acute myeloid leukemia, acute leukemia
Frequency not reported: Headache, drowsiness, syncope
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Mutamycin